Investors' first priority is usually banks when it comes to investing their hard-earned money.

S&P BSE IPO index, which is based on the strategy of tracking the performance of the recently-listed IPOs, has been able to outperform Sensex almost on every other timeframe that we want to consider.  
 

The stock is expected to witness buying momentum in coming sessions owing to excellent quarterly results declared this season.

Markets are in great shape and Sensex while trading at life highs is helping build a positive sentiment and feel-good factor about being an investor in equity markets. The positive sentiment is leading to increased participation in the markets and with increased participation the demand for small caps, microcaps and penny stocks is on the rise.  
 

Ruchi Soya Industries: Ruchi Soya Industries has forayed into the nutraceuticals & wellness products segment. The company's board of directors approved the launch of 100 per cent vegetarian, preservative-free nutraceutical products to be marketed under 'Patanjali' and 'Nutrela' branding in the medical, sports, and general nutrition categories.

Sun Pharmaceutical Industries Ltd announced today that one of its wholly-owned subsidiaries has entered into a licence agreement with Ferring Pharmaceuticals Private Limited, a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialise a room temperature stable (RTS) formulation of the obstetric drug, CARITEC (Carbetocin RTS) in India.  

The shares of Ratnamani Metals & Tubes Ltd (RMTL) were trading in the green on Wednesday after the company announced that it has secured an order for carbon steel pipes worth Rs 81.79 crore.   

Tata Power Limited’s wholly-owned subsidiary, Tata Power Solar has received a letter of award (LoA) to build 210 MWp of solar PV projects for NTPC. The total order value of the projects is Rs 686 crore while its commissioning date has been set for November 2022. 

Ramco Systems, a next-gen enterprise software company, announced today that it has been selected by Bristow Group Inc., a leading global provider of vertical flight solutions to digitally transform the maintenance & engineering operations of the latter.  

Lupin Ltd, a global pharmaceutical company, announced today that it has received the approval from United States Food & Drug Administration (USFDA) for its biologics license application (BLA) of its biosimilar to Neulasta (pegfilgrastim).